Sanofi : Attractive growth and momentum
>Positive momentum – Buy recommendation and target price of € 91 confirmed - This morning we recap on our investment case for Sanofi based on: i) an attractive valuation with 2018-2022e EPS CAGR of 9% vs 8% for the rest of the sector, which gives it an attractive PEG of 1.4x vs 1.7x (median for the sector excl. Bayer for the two), ii) positive momentum in the short term, iii) short-term commercial and clinical newsflow. We reiterate our Buy recommendation and target p...Sanofi is an integrated, global healthcare company focused on patient needs and engaged in the research, development, manufacture and marketing of healthcare products. Two segments make up Co.'s business: Pharmaceuticals and Vaccines. The Pharmaceuticals segment covers research, development, production and marketing of medicines, consisting of flagship products, plus a broad range of prescription medicines, generic medicines, and consumer health products. The Vaccines segment includes research, development, production and marketing of vaccines in five areas: pediatric vaccines, influenza vaccines, adult and adolescent booster vaccines, meningitis vaccines, and travel and endemic vaccines.
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.